Bavencio

Chemical Nameavelumab
Dosage FormInjection (intravenous; 200 mg/10 mL (20 mg/mL))
Drug ClassMonoclonal antibodies
SystemSkin, Urinary
CompanyEMD Serono
Approval Year2017

Indication

  • Indicated for adults and pediatric patients 12 years and older with metastatic Merkel Cell Carcinoma (MCC)
  • Indicated for the maintenance treatment of patients with locally advanced or metastatic Urothelial Carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy
  • Indicated for patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
  • Indicated for first-line treatment, in combination with axitinib, of patients with advanced Renal Cell Carcinoma (RCC)
Last updated on 5/2/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bavencio (Avelumab) Prescribing Information.2020EMD Serono, Inc., Rockland, MA
Document TitleYearSource
Muscle-invasive and metastatic bladder cancer. 2022European Association of Urology
Renal cell carcinoma. 2022European Association of Urology
Bladder cancer, version 3.2020. 2020Journal of the National Comprehensive Cancer Network
SEOM clinical guideline for treatment of kidney cancer (2019). 2020Clinical and Translational Oncology
NCCN guidelines insights: kidney cancer, version 2.2020. 2019Journal of the National Comprehensive Cancer Network
Merkel cell carcinoma, version 1.2018. 2018Journal of the National Comprehensive Cancer Network
Society for Immunotherapy of cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. 2017Journal for ImmunoTherapy of Cancer